questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Transferases
Phosphotransferases
Phosphotransferases (Phosphate Group Acceptor)
Phosphotransferases (Phosphate Group Acceptor) : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Déficience enzymatique
Phosphotransférases
Tests de laboratoire
Phosphotransférases
Symptômes métaboliques
Phosphotransférases
Tests génétiques
Phosphotransférases
Imagerie médicale
Phosphotransférases
Symptômes
5
Fatigue
Phosphotransférases
Troubles neurologiques
Phosphotransférases
Enzymes
Phosphotransférases
Symptômes néonatals
Phosphotransférases
Retard de développement
Phosphotransférases
Prévention
5
Prévention
Phosphotransférases
Dépistage néonatal
Phosphotransférases
Recommandations diététiques
Phosphotransférases
Conseils génétiques
Phosphotransférases
Vaccination
Phosphotransférases
Traitements
5
Traitement nutritionnel
Phosphotransférases
Thérapie génique
Phosphotransférases
Médicaments
Phosphotransférases
Essais cliniques
Phosphotransférases
Gestion diététique
Phosphotransférases
Complications
5
Complications métaboliques
Phosphotransférases
Troubles cardiaques
Phosphotransférases
Qualité de vie
Phosphotransférases
Complications
Phosphotransférases
Maladies métaboliques
Phosphotransférases
Facteurs de risque
5
Facteurs de risque
Phosphotransférases
Facteurs environnementaux
Phosphotransférases
Maladies auto-immunes
Phosphotransférases
Alimentation
Phosphotransférases
Infections
Phosphotransférases
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Phosphotransferases (Phosphate Group Acceptor) : Questions médicales les plus fréquentes",
"headline": "Phosphotransferases (Phosphate Group Acceptor) : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Phosphotransferases (Phosphate Group Acceptor) : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-31",
"dateModified": "2025-04-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Phosphotransferases (Phosphate Group Acceptor)"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Phosphotransferases",
"url": "https://questionsmedicales.fr/mesh/D010770",
"about": {
"@type": "MedicalCondition",
"name": "Phosphotransferases",
"code": {
"@type": "MedicalCode",
"code": "D010770",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Adenylate kinase",
"alternateName": "Adenylate Kinase",
"url": "https://questionsmedicales.fr/mesh/D000263",
"about": {
"@type": "MedicalCondition",
"name": "Adenylate kinase",
"code": {
"@type": "MedicalCode",
"code": "D000263",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.025"
}
}
},
{
"@type": "MedicalWebPage",
"name": "ATP synthetase complexes",
"alternateName": "ATP Synthetase Complexes",
"url": "https://questionsmedicales.fr/mesh/D025181",
"about": {
"@type": "MedicalCondition",
"name": "ATP synthetase complexes",
"code": {
"@type": "MedicalCode",
"code": "D025181",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.150"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Guanylate kinase",
"alternateName": "Guanylate Kinases",
"url": "https://questionsmedicales.fr/mesh/D051528",
"about": {
"@type": "MedicalCondition",
"name": "Guanylate kinase",
"code": {
"@type": "MedicalCode",
"code": "D051528",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Nucleoside diphosphate kinase",
"alternateName": "Nucleoside-Diphosphate Kinase",
"url": "https://questionsmedicales.fr/mesh/D009701",
"about": {
"@type": "MedicalCondition",
"name": "Nucleoside diphosphate kinase",
"code": {
"@type": "MedicalCode",
"code": "D009701",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.550"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "NM23 Nucleoside Diphosphate kinases",
"alternateName": "NM23 Nucleoside Diphosphate Kinases",
"url": "https://questionsmedicales.fr/mesh/D054778",
"about": {
"@type": "MedicalCondition",
"name": "NM23 Nucleoside Diphosphate kinases",
"code": {
"@type": "MedicalCode",
"code": "D054778",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.550.200"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Nucleoside phosphate kinase",
"alternateName": "Nucleoside-Phosphate Kinase",
"url": "https://questionsmedicales.fr/mesh/D009703",
"about": {
"@type": "MedicalCondition",
"name": "Nucleoside phosphate kinase",
"code": {
"@type": "MedicalCode",
"code": "D009703",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.913.696.650.575"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Phosphotransferases (Phosphate Group Acceptor)",
"alternateName": "Phosphotransferases (Phosphate Group Acceptor)",
"code": {
"@type": "MedicalCode",
"code": "D017856",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jean-Marc Jeckelmann",
"url": "https://questionsmedicales.fr/author/Jean-Marc%20Jeckelmann",
"affiliation": {
"@type": "Organization",
"name": "Institute of Biochemistry and Molecular Medicine, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland. jean-marc.jeckelmann@ibmm.unibe.ch."
}
},
{
"@type": "Person",
"name": "Zengqi Xie",
"url": "https://questionsmedicales.fr/author/Zengqi%20Xie",
"affiliation": {
"@type": "Organization",
"name": "Institute of Polymer Optoelectronic Materials and Devices, South China University of Technology, Guangzhou 510640, China."
}
},
{
"@type": "Person",
"name": "Bernhard Erni",
"url": "https://questionsmedicales.fr/author/Bernhard%20Erni",
"affiliation": {
"@type": "Organization",
"name": "Institute of Biochemistry and Molecular Medicine, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland."
}
},
{
"@type": "Person",
"name": "Yulin Zhu",
"url": "https://questionsmedicales.fr/author/Yulin%20Zhu",
"affiliation": {
"@type": "Organization",
"name": "Shenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China."
}
},
{
"@type": "Person",
"name": "Feng He",
"url": "https://questionsmedicales.fr/author/Feng%20He",
"affiliation": {
"@type": "Organization",
"name": "Shenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Amblyopia and the whole child.",
"datePublished": "2023-02-01",
"url": "https://questionsmedicales.fr/article/36736071",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.preteyeres.2023.101168"
}
},
{
"@type": "ScholarlyArticle",
"name": "Amblyopia and fixation eye movements.",
"datePublished": "2022-08-03",
"url": "https://questionsmedicales.fr/article/36007287",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jns.2022.120373"
}
},
{
"@type": "ScholarlyArticle",
"name": "Postural stability in strabismus and amblyopia.",
"datePublished": "2023-07-25",
"url": "https://questionsmedicales.fr/article/37489251",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/09273972.2023.2236138"
}
},
{
"@type": "ScholarlyArticle",
"name": "Subthreshold Amblyopia: Characterization of a New Cohort.",
"datePublished": "2022-12-18",
"url": "https://questionsmedicales.fr/article/36543314",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ajo.2022.12.015"
}
},
{
"@type": "ScholarlyArticle",
"name": "Binocular treatment for amblyopia: a systematic review.",
"datePublished": "2024-09-02",
"url": "https://questionsmedicales.fr/article/39222269",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10792-024-03259-7"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Transferases",
"item": "https://questionsmedicales.fr/mesh/D014166"
},
{
"@type": "ListItem",
"position": 5,
"name": "Phosphotransferases",
"item": "https://questionsmedicales.fr/mesh/D010770"
},
{
"@type": "ListItem",
"position": 6,
"name": "Phosphotransferases (Phosphate Group Acceptor)",
"item": "https://questionsmedicales.fr/mesh/D017856"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Phosphotransferases (Phosphate Group Acceptor) - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Comment diagnostiquer une déficience en phosphotransférases ?\nQuels tests sont utilisés pour évaluer l'activité des phosphotransférases ?\nQuels symptômes peuvent indiquer un problème avec ces enzymes ?\nLes tests génétiques sont-ils utiles pour le diagnostic ?\nPeut-on diagnostiquer par imagerie des troubles liés aux phosphotransférases ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Amblyopia#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quels sont les symptômes d'une déficience en phosphotransférases ?\nLes troubles neurologiques sont-ils liés aux phosphotransférases ?\nComment les symptômes varient-ils selon le type d'enzyme ?\nLes symptômes apparaissent-ils à la naissance ?\nY a-t-il des symptômes spécifiques aux enfants ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Amblyopia#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Peut-on prévenir les déficiences en phosphotransférases ?\nLes tests de dépistage néonatal sont-ils utiles ?\nY a-t-il des recommandations diététiques préventives ?\nLes conseils génétiques sont-ils importants ?\nLes vaccinations peuvent-elles aider à prévenir des complications ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Amblyopia#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quels traitements sont disponibles pour les déficiences en phosphotransférases ?\nLa thérapie génique est-elle une option ?\nLes médicaments peuvent-ils aider à traiter ces déficiences ?\nY a-t-il des traitements expérimentaux en cours ?\nComment la gestion diététique aide-t-elle ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Amblyopia#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quelles complications peuvent survenir avec ces déficiences ?\nLes troubles cardiaques sont-ils une complication possible ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications sont-elles réversibles ?\nY a-t-il un risque accru de maladies métaboliques ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Amblyopia#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Phosphotransferases (Phosphate Group Acceptor)",
"description": "Quels sont les facteurs de risque pour ces déficiences ?\nLes facteurs environnementaux jouent-ils un rôle ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nL'alimentation peut-elle influencer le risque ?\nLes infections peuvent-elles aggraver la condition ?",
"url": "https://questionsmedicales.fr/mesh/D017856?mesh_terms=Amblyopia#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en phosphotransférases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des analyses biochimiques sont utilisés pour évaluer l'activité des phosphotransférases."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des phosphotransférases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de dosage enzymatique et les analyses de métabolites sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec ces enzymes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes métaboliques, comme la fatigue ou des troubles énergétiques, peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier des mutations affectant les phosphotransférases."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer par imagerie des troubles liés aux phosphotransférases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est pas spécifique, mais peut aider à évaluer des complications métaboliques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en phosphotransférases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, faiblesse musculaire, troubles de la croissance et anomalies métaboliques."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques sont-ils liés aux phosphotransférases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent survenir en raison d'un métabolisme énergétique altéré."
}
},
{
"@type": "Question",
"name": "Comment les symptômes varient-ils selon le type d'enzyme ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes dépendent de l'enzyme spécifique affectée et de son rôle métabolique."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils à la naissance ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains symptômes peuvent apparaître à la naissance, tandis que d'autres se développent plus tard."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux enfants ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les enfants peuvent présenter des retards de développement et des troubles de la croissance."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les déficiences en phosphotransférases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Les tests de dépistage néonatal sont-ils utiles ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests de dépistage néonatal peuvent identifier certaines déficiences précocement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations diététiques préventives ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recommandations diététiques peuvent être établies pour les familles à risque."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les conseils génétiques peuvent aider les familles à comprendre les risques de transmission."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider à prévenir des complications ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations ne préviennent pas directement les déficiences, mais protègent contre les infections."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les déficiences en phosphotransférases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des suppléments nutritionnels et une gestion diététique."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore largement disponible pour ces déficiences."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à traiter ces déficiences ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent aider à gérer les symptômes, mais ne corrigent pas la déficience."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux en cours ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études cliniques explorent de nouvelles approches thérapeutiques pour ces conditions."
}
},
{
"@type": "Question",
"name": "Comment la gestion diététique aide-t-elle ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une gestion diététique peut aider à compenser les déficiences métaboliques et à améliorer la santé."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces déficiences ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications métaboliques, neurologiques et de croissance peuvent se développer."
}
},
{
"@type": "Question",
"name": "Les troubles cardiaques sont-ils une complication possible ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles cardiaques peuvent survenir en raison d'un métabolisme énergétique altéré."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent réduire la qualité de vie en limitant les activités quotidiennes."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de maladies métaboliques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes avec des déficiences en phosphotransférases peuvent avoir un risque accru de maladies métaboliques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour ces déficiences ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et certaines mutations génétiques sont des facteurs de risque connus."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains facteurs environnementaux peuvent influencer l'expression des déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies auto-immunes peuvent affecter le métabolisme et augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'alimentation peut-elle influencer le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation déséquilibrée peut exacerber les symptômes chez les personnes à risque."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles aggraver la condition ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections peuvent déclencher ou aggraver les symptômes liés aux déficiences enzymatiques."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 27/04/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Institute of Biochemistry and Molecular Medicine, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland. jean-marc.jeckelmann@ibmm.unibe.ch.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
3 publications dans cette catégorie
Affiliations :
Institute of Polymer Optoelectronic Materials and Devices, South China University of Technology, Guangzhou 510640, China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Institute of Biochemistry and Molecular Medicine, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Shenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Shenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, Shenzhen 518055, China.
Guangdong Provincial Key Laboratory of Catalysis, Southern University of Science and Technology, Shenzhen 518055, China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Hoffmann Institute of Advanced Materials, Shenzhen Polytechnic University, 7098 Liuxian Blvd, District Nanshan, Shenzhen, 518055, P. R. China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo 315201, China.
Center of Materials Science and Optoelectronics Engineer, University of Chinese Academy of Sciences, Beijing 100049, China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo 315201, China.
Center of Materials Science and Optoelectronics Engineer, University of Chinese Academy of Sciences, Beijing 100049, China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Institute of Polymer Optoelectronic Materials and Devices, South China University of Technology, Guangzhou 510640, China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Center for Advanced Low-Dimension Materials, State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, College of Materials Science and Engineering, Donghua University, Shanghai 201620, P. R. China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Institute of Polymer Optoelectronic Materials and Devices and State Key Laboratory of Luminescent Materials and Devices, South China University of Technology, Guangzhou 510640, P. R. China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Dokkyo Medical University School of Medicine, Mibu, Tochigi 321-0293, Japan.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Dokkyo Medical University School of Medicine, Mibu, Tochigi 321-0293, Japan h-sugi@dokkyomed.ac.jp.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
2 publications dans cette catégorie
Affiliations :
Department of Microbiology, Assam University, Silchar, Assam, India.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
1 publication dans cette catégorie
Affiliations :
Department of Biochemistry, McGill University, Montreal, QC H3G 0B1, Canada.
Department of Anatomy and Cell Biology, McGill University, Montreal, QC H3A 0C7, Canada.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
1 publication dans cette catégorie
Affiliations :
Department of Biochemistry, McGill University, Montreal, QC H3G 0B1, Canada.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
1 publication dans cette catégorie
Affiliations :
Department of Anatomy and Cell Biology, McGill University, Montreal, QC H3A 0C7, Canada.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
1 publication dans cette catégorie
Affiliations :
Department of Biochemistry, McGill University, Montreal, QC H3G 0B1, Canada.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Biocatalysis and Enzyme Engineering, Hubei Key Laboratory of Industrial Biotechnology, School of Life Sciences, Hubei University, Wuhan 430062, China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Biocatalysis and Enzyme Engineering, Hubei Key Laboratory of Industrial Biotechnology, School of Life Sciences, Hubei University, Wuhan 430062, China.
Publications dans "Phosphotransferases (Phosphate Group Acceptor)" :
Amblyopia is a disorder of neurodevelopment that occurs when there is discordant binocular visual experience during the first years of life. While treatments are effective in improving visual acuity, ...
Amblyopia is a neurodevelopmental disorder caused by abnormal visual experience in early life that affects 3-5% of the population. Amblyopia results in a host of monocular and binocular visual afferen...
Postural control is a complex skill based on the collaboration of dynamic sensory mechanisms, namely the visual, vestibular, and somatosensory systems....
A literature survey regarding postural stability in strabismus and amblyopia was conducted using databases in order to collect data for a narrative review of published reports and available literature...
The results of the literature survey were analyzed to provide an overview of the current knowledge of postural stability in strabismus and amblyopia. The results revealed that although postural contro...
Binocular vision is imperative for the maturation and preservation of balance control in children, as balance performance is reduced in strabismus and/or amblyopia....
Published studies of amblyopia include only patients with visual acuity (VA) worse than 20/40 in one or both eyes. The purpose of this study is to evaluate patients diagnosed and treated as amblyopic ...
Retrospective clinical cohort study....
Setting: Institutional practice....
All patients diagnosed with amblyopia at Boston Children's Hospital between 2010 and 2014....
VA better than 20/40 but not correctable to 20/20 in one or both eyes; age 2 to 12 years....
Demographics, VA, baseline characteristics....
Resolution, defined as VA 20/20 in both eyes; stereopsis at the last follow-up....
Of 2311 patients reviewed, 464 (20.1%) had subthreshold amblyopia. A majority (61.7%) had an amblyogenic factor, most commonly anisometropia (32.8%). Patients were followed for a median of 3.1 years; ...
Patients with subthreshold amblyopia represent a sizeable cohort in real-world amblyopia practice. When offered treatment, half achieved 20/20 vision in both eyes with improved stereopsis as well. Fur...
The treatment of unilateral amblyopia involves refractive adaptation, occlusion therapy or penalization with atropine drops. However, in recent years, the use of binocular digital therapy has shown pr...
This systematic review was conducted in accordance to PRISMA statement. Electronic literature was thoroughly searched for articles published between 2013 and May 2024, in the following electronic data...
Twenty RCTs, including 1769 patients, were incorporated into this systematic review. Twelve different types of binocular amblyopia treatments were identified and categorized into two main types. The f...
Binocular amblyopia treatment has shown promising results in addressing unilateral anisometropic, strabismic or mixed type of amblyopia. Nevertheless, further randomized controlled trials are essentia...
Standard-of-care assessment for children with amblyopia includes measuring amblyopic eye best-corrected visual acuity (AE BCVA) with the fellow eye occluded. By definition, this abolishes the interocu...
Cross-sectional study....
Dichoptic and monocular AE BCVA of children aged 6-12 years (42 with amblyopia, 24 with recovered normal AE BCVA, 30 control) were measured. Stereoacuity, suppression, eye-hand coordination, and readi...
Overall, 81% of amblyopic children had worse dichoptic than monocular AE BCVA (mean difference=0.15±0.11 logMAR; P < .0001), and 71% of children with recovered normal AE BCVA had worse dichoptic than ...
Dichoptic AE BCVA deficits were worse than monocular AE BCVA deficits and were associated with reduced stereoacuity and suppression, consistent with the hypothesis that binocular dysfunction plays a r...
To compare amblyopia treatment outcomes between patients with neurodevelopmental disorders and their typically developing peers....
Of 2,311 patients diagnosed with amblyopia between 2010 and 2014 at Boston Children's Hospital, 460 met inclusion criteria (age 2-12 with anisometropic, strabismic, or mixed amblyopia [interocular dif...
The DD group (n = 54) and TD group (n = 406) were similar in demographics, amblyogenic risk factors, baseline visual measures, prescribed therapy, and adherence (P ≥ 0.10). Between-visit follow-up tim...
Patients with DD and those with TD responded similarly to amblyopia therapy; however, follow-up intervals were longer in patients with DD and correlated with the likelihood of persistent amblyopia, su...
To determine whether deficits in manual dexterity in children with amblyopia improve after binocular amblyopia treatment and whether improvements are related to age at treatment, baseline sensory stat...
Manual dexterity (Movement Assessment Battery for Children-2), visual acuity, fusion, suppression, and stereoacuity were measured at baseline and after 4-8 weeks of binocular amblyopia in 134 children...
Baseline manual dexterity standard scores of amblyopic children were significantly below those of controls in both the younger (8.81 ± 0.33 vs 11.80 ± 0.60 [P < 0.0001]) and older groups (7.19 ± 0.34 ...
To compare the macular and papillary parameters on optical coherence tomography (OCT) between the amblyopic eye and the healthy eye in subjects with unilateral strabismic or anisometropic amblyopia....
This is a cross-sectional and comparative study carried out over two years, from April 1, 2019, to March 31, 2021. We included patients aged over 5years, followed for unilateral amblyopia, free of any...
We collected 50 patients, 29 children, and 21 adults, with a mean age of 19.8years. Amblyopia was secondary to anisometropia in 40 patients and strabismus in 10 patients. Analysis of macular tomograph...
Amblyopia is accompanied by thickening of the peripapillary retinal fibers without macular repercussions. However, larger prospective studies are needed to confirm these results....
To determine the optical coherence tomography angiography (OCTA) parameters including foveal avascular zone (FAZ) and vessel density (VD) in the amblyopic eyes compared with the fellow sound eyes and ...